Skip to main content

Table 3 Logistic regression of possible risk factors and clinical hepatitis

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Risk factors

Odd Ratios

95% confidence interval

Pvalue

Female gender

1.25

0.21–7.49

0.809

Body weight

1.08

0.98–1.17

0.076

Baseline CD4 cell count

0.99

0.97–1.01

0.352

Receiving anti-tuberculous drugs

7.42

1.27–43.31

0.026

Receiving fluconazole

1.12

0.18–6.90

0.901

Receiving Cotrimoxazole

0.84

0.21–5.44

0.675